2019
DOI: 10.1016/j.jccase.2019.05.001
|View full text |Cite
|
Sign up to set email alerts
|

Persistent heart failure following melphalan and fludarabine conditioning

Abstract: Advances in chemotherapy and radiotherapy have had the greatest impact on cancer survival, but their combined side effects have led patients to deal with serious organic complications as a result of their treatment. In attempting to treat the cancer, many times anti-cancer therapies cause complications that need treatment themselves. Frequently, use of these agents in combination will result in the addition of toxicities and can exponentially increase their side-effect profile. Even whilst these drugs are used… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 8 publications
0
4
0
Order By: Relevance
“…Melphalan cardiotoxicity presents more commonly as atrial fibrillation and supraventricular tachycardia [16], but ventricular arrhythmias have also been reported [17]. There is also an association between melphalan and heart failure [12,18,19], but the underlying mechanism is unknown. A cumulative dose of bortezomib is an important consideration because it has been associated with an increased risk of cardiac side effects [7].…”
Section: Discussionmentioning
confidence: 99%
“…Melphalan cardiotoxicity presents more commonly as atrial fibrillation and supraventricular tachycardia [16], but ventricular arrhythmias have also been reported [17]. There is also an association between melphalan and heart failure [12,18,19], but the underlying mechanism is unknown. A cumulative dose of bortezomib is an important consideration because it has been associated with an increased risk of cardiac side effects [7].…”
Section: Discussionmentioning
confidence: 99%
“…Other clinical antimetabolites for tumor treatment have also been reported to be associated with cardiotoxicity, such as HF caused by fludarabine and pericarditis caused by cytarabine. However, research on their mechanism of action is lacking [140][141][142].…”
Section: Antimetabolitesmentioning
confidence: 99%
“…melphalan) can result in cardiac dysfunction. In patients with hematological malignancies both fatal and non-fatal congestive heart failure, 13 , 14 acute severe left ventricular failure, 15 , 16 hypotension and chest pain, 17 and myocarditis 18 have been observed. None of the patients in these studies had prior cardiac dysfunction.…”
Section: Introductionmentioning
confidence: 99%